Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Depreciation & Amortization (CF): 2020-2024

Historic Depreciation & Amortization (CF) for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to $287,000.

  • Therapeutics' Depreciation & Amortization (CF) fell 9.18% to $287,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $1.2 million, marking a year-over-year decrease of 1.23%. This contributed to the annual value of $1.2 million for FY2024, which is 1.07% down from last year.
  • Per Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $287,000 for Q4 2024, which was down 4.33% from $300,000 recorded in Q3 2024.
  • Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $400,000 during Q2 2020, with a 5-year trough of $199,000 in Q1 2020.
  • In the last 3 years, Therapeutics' Depreciation & Amortization (CF) had a median value of $300,000 in 2024 and averaged $288,667.
  • The largest annual percentage gain for Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 50.75% (2021), contrasted with its biggest fall of 50.00% (2021).
  • Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $223,000 in 2020, then declined by 10.31% to $200,000 in 2021, then grew by 23.50% to $247,000 in 2022, then increased by 27.94% to $316,000 in 2023, then declined by 9.18% to $287,000 in 2024.
  • Its last three reported values are $287,000 in Q4 2024, $300,000 for Q3 2024, and $300,000 during Q2 2024.